GREENLAND MINES LTD Payments of Stock Issuance Costs
GREENLAND MINES LTD (GRML) reported Payments of Stock Issuance Costs of $1.53 million for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-08-17.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-17
- GREENLAND MINES LTD payments of stock issuance costs for the quarter ending 2023-12-31 was $39.26M.
- GREENLAND MINES LTD payments of stock issuance costs for the quarter ending 2023-09-30 was $0.00.
- GREENLAND MINES LTD payments of stock issuance costs for the quarter ending 2022-03-31 was $221.06K.
- GREENLAND MINES LTD payments of stock issuance costs for fiscal 2023 was $102.42M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.53M 10-Q · filed 2026-08-17 | |||
| 2023-12-31 | $39.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-17 | $39.26M derived: sum of 2 quarters · filed 2024-04-17 | $102.42M 10-K · filed 2024-04-17 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | $63.17M 10-Q · filed 2023-11-17 | ||
| 2023-06-30 | $63.17M 10-Q · filed 2023-08-21 | |||
| 2022-03-31 | $221.06K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |